CY1116187T1 - Παρεντερικη φαρμακευτικη μορφη h οποια απελευθερωνει αναστολεα αρωματασης και γεσταγονα, για τη θεραπευτικη αγωγη ενδομητριωσης - Google Patents

Παρεντερικη φαρμακευτικη μορφη h οποια απελευθερωνει αναστολεα αρωματασης και γεσταγονα, για τη θεραπευτικη αγωγη ενδομητριωσης

Info

Publication number
CY1116187T1
CY1116187T1 CY20151100269T CY151100269T CY1116187T1 CY 1116187 T1 CY1116187 T1 CY 1116187T1 CY 20151100269 T CY20151100269 T CY 20151100269T CY 151100269 T CY151100269 T CY 151100269T CY 1116187 T1 CY1116187 T1 CY 1116187T1
Authority
CY
Cyprus
Prior art keywords
gastagon
aromatology
inhabitants
releases
therapeutic
Prior art date
Application number
CY20151100269T
Other languages
English (en)
Inventor
Arto Pakkalin
Rudolf Knauthe
Heinz Schmitz
Christine Talling
Harri Jukarainen
Henriikka Korolainen
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116187(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of CY1116187T1 publication Critical patent/CY1116187T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Το περιεχόμενο της παρούσας εφεύρεσης για τη θεραπευτική αγωγή της ενδομητρίωσης είναι η διάθεση παρεντερικής φαρμακευτικής μορφής (σύστημα απελευθέρωσης) για την ελεγχόμενη απελευθέρωση αναστολέα αρωματάσης (ΑΙ) με ημερήσιο ρυθμό απελευθέρωσης ο οποίος δεν επάγει διέγερση των ωοθηκών μέσω αρνητικής ανάδρασης του άξονα υπόφυσης-ωοθηκών (η οποία θα προκαλούσε έκκριση γοναδοτροπινών και διέγερση της ωοθηκικής αύξησης θυλακίου), και γεσταγόνου με ημερήσιο ρυθμό απελευθέρωσης κάτω από τη δόση αναστολής ωορρηξίας, ο οποίος προσφέρει αντισυλληπτική δράση στη βάση τοπικών δράσεων (για παράδειγμα ελάττωση και πάχυνση της τραχηλικής βλέννας για την αποτροπή της ανόδου σπερματοζωαρίων, δράσεις πάνω στο ενδομήτριο και στην ευκινησία σωλήνων, για την παρεμπόδιση της εμφύτευσης και της μεταφοράς ωαρίων).
CY20151100269T 2010-03-31 2015-03-17 Παρεντερικη φαρμακευτικη μορφη h οποια απελευθερωνει αναστολεα αρωματασης και γεσταγονα, για τη θεραπευτικη αγωγη ενδομητριωσης CY1116187T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP11714245.5A EP2552404B1 (de) 2010-03-31 2011-03-28 Parenterale arzneiform, die aromatasehemmer und gestagene freisetzt, für die behandlung von endometriose

Publications (1)

Publication Number Publication Date
CY1116187T1 true CY1116187T1 (el) 2017-02-08

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100269T CY1116187T1 (el) 2010-03-31 2015-03-17 Παρεντερικη φαρμακευτικη μορφη h οποια απελευθερωνει αναστολεα αρωματασης και γεσταγονα, για τη θεραπευτικη αγωγη ενδομητριωσης

Country Status (41)

Country Link
US (2) US20130131027A1 (el)
EP (1) EP2552404B1 (el)
JP (2) JP6012048B2 (el)
KR (1) KR20130010047A (el)
CN (1) CN103002873B (el)
AR (1) AR080861A1 (el)
AU (1) AU2011234587B2 (el)
BR (1) BR112012024739A2 (el)
CA (1) CA2794790A1 (el)
CL (1) CL2012002722A1 (el)
CO (1) CO6630125A2 (el)
CR (1) CR20120493A (el)
CU (1) CU20120145A7 (el)
CY (1) CY1116187T1 (el)
DE (1) DE102010003494A1 (el)
DK (1) DK2552404T3 (el)
DO (1) DOP2012000255A (el)
EA (1) EA025582B1 (el)
EC (1) ECSP12012176A (el)
ES (1) ES2533101T3 (el)
GT (1) GT201200267A (el)
HK (1) HK1179531A1 (el)
HR (1) HRP20150294T1 (el)
IL (1) IL222056A (el)
MA (1) MA34099B1 (el)
ME (1) ME02159B (el)
MX (1) MX2012011329A (el)
MY (1) MY160353A (el)
NZ (1) NZ602698A (el)
PE (1) PE20130524A1 (el)
PL (1) PL2552404T3 (el)
PT (1) PT2552404E (el)
RS (1) RS53876B1 (el)
SG (1) SG184111A1 (el)
SI (1) SI2552404T1 (el)
TN (1) TN2012000468A1 (el)
TW (2) TW201632184A (el)
UA (1) UA109655C2 (el)
UY (1) UY33303A (el)
WO (1) WO2011120925A1 (el)
ZA (1) ZA201206869B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN107850568A (zh) * 2015-05-27 2018-03-27 奎斯特诊断投资有限公司 用于质谱定量由微量取样装置提取的分析物的方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
UA124382C2 (uk) * 2015-12-21 2021-09-08 Баєр Ой Спосіб виготовлення пристрою для доставки лікарського засобу
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
WO2022174074A1 (en) * 2021-02-12 2022-08-18 The Regents Of The University Of California Endometriosis-related methods and compositions
CN115804762A (zh) * 2022-12-20 2023-03-17 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572A (fi) * 2000-03-13 2001-09-14 Leiras Oy Implantaattien asettamiseen tarkoitettu laite
MXPA03006607A (es) * 2001-01-26 2003-09-22 Upjohn Co Metodo combinado para tratar trastornos dependientes de hormonas.
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) * 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
JP6012048B2 (ja) 2016-10-25
CO6630125A2 (es) 2013-03-01
TW201201799A (en) 2012-01-16
WO2011120925A1 (de) 2011-10-06
JP2013523683A (ja) 2013-06-17
CN103002873A (zh) 2013-03-27
AU2011234587B2 (en) 2015-07-09
PL2552404T3 (pl) 2015-05-29
GT201200267A (es) 2014-06-04
UY33303A (es) 2011-10-31
HRP20150294T1 (hr) 2015-06-19
EA025582B1 (ru) 2017-01-30
MA34099B1 (fr) 2013-03-05
ES2533101T3 (es) 2015-04-07
PE20130524A1 (es) 2013-04-26
IL222056A (en) 2016-03-31
EP2552404A1 (de) 2013-02-06
EA201201358A1 (ru) 2013-04-30
CA2794790A1 (en) 2011-10-06
ZA201206869B (en) 2016-01-27
SG184111A1 (en) 2012-10-30
TW201632184A (zh) 2016-09-16
PT2552404E (pt) 2015-03-30
CR20120493A (es) 2012-11-22
ME02159B (me) 2015-10-20
KR20130010047A (ko) 2013-01-24
AR080861A1 (es) 2012-05-16
UA109655C2 (uk) 2015-09-25
SI2552404T1 (sl) 2015-04-30
JP2016164200A (ja) 2016-09-08
DOP2012000255A (es) 2013-04-30
CL2012002722A1 (es) 2013-01-18
ECSP12012176A (es) 2012-10-30
MY160353A (en) 2017-02-28
RS53876B1 (en) 2015-08-31
HK1179531A1 (en) 2013-10-04
CN103002873B (zh) 2015-02-18
CU20120145A7 (es) 2013-05-31
MX2012011329A (es) 2012-11-30
NZ602698A (en) 2014-08-29
AU2011234587A1 (en) 2012-10-25
US20150359802A1 (en) 2015-12-17
DK2552404T3 (en) 2015-03-30
TWI576107B (zh) 2017-04-01
TN2012000468A1 (en) 2014-01-30
EP2552404B1 (de) 2015-01-21
DE102010003494A1 (de) 2011-10-06
US20130131027A1 (en) 2013-05-23
BR112012024739A2 (pt) 2016-06-07

Similar Documents

Publication Publication Date Title
CY1116187T1 (el) Παρεντερικη φαρμακευτικη μορφη h οποια απελευθερωνει αναστολεα αρωματασης και γεσταγονα, για τη θεραπευτικη αγωγη ενδομητριωσης
EA201490251A1 (ru) Внутриматочные системы, устройства введения устройств iud (внутриматочных устройств) и связанные с ними способы и наборы
BR112014013499A8 (pt) sistema de entrega de dispositivo médico, linha de atar, método de implantação de um dispositivo médico e dispositivo médico
CY1114260T1 (el) 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγο, μεθοδοι για την παραγωγη αυτου και χρηση αυτου για την αγωγη παθησεων
CL2016003295A1 (es) Dosificación intermitente de un inhibidor de mdm2.
MX2015001938A (es) Dispositivo anticonceptivo intrauterino.
MX2016005142A (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
CY1122190T1 (el) Ενωσεις για την προφυλαξη και την αντιμετωπιση της διαδικασιας συμφυσης
RU2012125066A (ru) Профилактическое средство и/или терапевтическое средство, и/или средство, подавляющее ухудшение при деформирующем артрите у человека
Chou et al. An unusual cause of dyspnea: giant hiatal hernia followed by Takotsubo cardiomyopathy
TH133904A (th) รูปแบบยาที่ไม่ผ่านทางเดินซึ่งปลดปล่อยสารยับยั้งอะโรมาเทสและเจสตาเจนเพื่อรักษาภาวะเยื่อบุมดลูกเจริญผิดที่
TH133904B (th) รูปแบบยาที่ไม่ผ่านทางเดินซึ่งปลดปล่อยสารยับยั้งอะโรมาเทสและเจสตาเจนเพื่อรักษาภาวะเยื่อบุมดลูกเจริญผิดที่
RU2013154813A (ru) Способ лечения впч-ассоциированных цервикальных неоплазий i степени с использованием кавитированного раствора иммунофана
RU2011149683A (ru) Способ лечения вторичного гипогонадизма у репродуктивно активных мужчин с ожирением
UA119099U (uk) Спосіб інтрацервікального штучного осіменіння свинок
AGENT MENOMETRORRHAGIA (IRREGULAR HEAVY MENSTRUAL BLEEDING)/MENORRHAGIA (HEAVY CYCLICAL MENSTRUAL BLEEDING)
Yuan et al. 400 Guo's Single-Armed Suture Technique for Microsurgical Vasoepididymostomy
Vinas Cetirizine/hydroxyzine
RU2013107834A (ru) Способ профилактики инфекционных осложнений после проведения хирургического аборта с использованием кавитированного водного раствора хлоргексидина
UA118050U (uk) Спосіб профілактики ускладнень після оперативних втручань на шийці матки
TH163150A (th) รูปแบบยาของโพรเจสเทอโรนรีเซปเตอร์แอนตะกอนิสต์
Sarghi Hepatotoxicity: case report
UA42875U (ru) Способ индукции овуляции при гиперандрогенном бесплодии
UA111345U (uk) Спосіб профілактики спайкової хвороби після лапароскопічних втручань з приводу позаматкової вагітності
UA112725U (uk) Спосіб стимуляції багатоплідності свиноматок